Adaptive Biotechnologies logo

Adaptive Biotechnologies

ADPT | NASDAQ
Chart Builder DCF Calculator
$27.87
-$1.17 (-4.03%)
At close: Nov 16, 2026, 4:00 PM ET
$27.87
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.03%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
38.9
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #558/1021 (Top 55%)

Key Statistics

Market Data

Market Cap $4.51B
1D Range
27.29 28.52
52W Range
12.41 30.26

Valuation (TTM)

PE -61.93
PB 25.60
EV/EBITDA -177.96

Valuation (NTM)

Forward PE N/A
Forward PEG 3.27
Price Target $33.00
Loading financial charts...

Profile

Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage ent...

Sector Healthcare
Industry Biotechnology
Employees 624
IPO Date Jun 27, 2019
Fiscal Year January - December

Latest News

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

6 days ago · globenewswire.com

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences
Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

6 days ago · zacks.com

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?
Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript

12 days ago · seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript
Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

12 days ago · zacks.com

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates
Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

12 days ago · zacks.com

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Adaptive Biotechnologies Q3 Earnings Call Highlights

12 days ago · marketbeat.com

Adaptive Biotechnologies Q3 Earnings Call Highlights
Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure

21 days ago · seekingalpha.com

Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure
Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

1 month ago · globenewswire.com

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100

1 month ago · gurufocus.com

Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

2 months ago · globenewswire.com

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Earnings

Latest Earnings
Nov 4, 2026
EPS
$0.02
Beat +121.96%
REV
$83.9M
Beat +17.23%
Next Earnings
Feb 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
6
Consensus
Buy
Price Target
$33.00
Upside
+18.41%
Buy (5)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.